AEON Biopharma (AEON) Competitors $0.77 +0.08 (+11.58%) Closing price 04:00 PM EasternExtended Trading$0.76 -0.01 (-1.16%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AEON vs. OKUR, ESLA, CLSD, BTAI, AKTX, SNYR, MURA, MAAQ, CASI, and TRIBShould you be buying AEON Biopharma stock or one of its competitors? The main competitors of AEON Biopharma include OnKure Therapeutics (OKUR), Estrella Immunopharma (ESLA), Clearside Biomedical (CLSD), BioXcel Therapeutics (BTAI), Akari Therapeutics (AKTX), Synergy CHC (SNYR), Mural Oncology (MURA), Mana Capital Acquisition (MAAQ), CASI Pharmaceuticals (CASI), and Trinity Biotech (TRIB). These companies are all part of the "pharmaceutical products" industry. AEON Biopharma vs. Its Competitors OnKure Therapeutics Estrella Immunopharma Clearside Biomedical BioXcel Therapeutics Akari Therapeutics Synergy CHC Mural Oncology Mana Capital Acquisition CASI Pharmaceuticals Trinity Biotech AEON Biopharma (NASDAQ:AEON) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership. Does the media favor AEON or OKUR? In the previous week, OnKure Therapeutics had 9 more articles in the media than AEON Biopharma. MarketBeat recorded 9 mentions for OnKure Therapeutics and 0 mentions for AEON Biopharma. OnKure Therapeutics' average media sentiment score of 0.86 beat AEON Biopharma's score of 0.00 indicating that OnKure Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment AEON Biopharma Neutral OnKure Therapeutics Positive Which has better earnings & valuation, AEON or OKUR? OnKure Therapeutics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAEON BiopharmaN/AN/A-$36.63M-$6.08-0.13OnKure TherapeuticsN/AN/A-$52.67M-$4.80-0.59 Do analysts prefer AEON or OKUR? AEON Biopharma presently has a consensus target price of $360.00, indicating a potential upside of 46,659.32%. OnKure Therapeutics has a consensus target price of $32.33, indicating a potential upside of 1,042.52%. Given AEON Biopharma's higher possible upside, research analysts clearly believe AEON Biopharma is more favorable than OnKure Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AEON Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00OnKure Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.14 Which has more risk and volatility, AEON or OKUR? AEON Biopharma has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Is AEON or OKUR more profitable? AEON Biopharma's return on equity of 0.00% beat OnKure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AEON BiopharmaN/A N/A -994.63% OnKure Therapeutics N/A -60.52%-55.43% Do institutionals & insiders believe in AEON or OKUR? 22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 0.9% of AEON Biopharma shares are held by insiders. Comparatively, 2.3% of OnKure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryOnKure Therapeutics beats AEON Biopharma on 9 of the 14 factors compared between the two stocks. Get AEON Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AEON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AEON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AEON vs. The Competition Export to ExcelMetricAEON BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.70M$835.01M$5.82B$9.73BDividend YieldN/A4.84%3.84%4.09%P/E Ratio4.281.1731.1525.96Price / SalesN/A26.53474.77122.97Price / CashN/A19.5637.1558.38Price / Book-0.196.639.116.39Net Income-$36.63M-$4.94M$3.26B$265.56M7 Day Performance0.25%0.95%2.12%1.98%1 Month Performance-4.24%2.99%5.13%1.33%1 Year Performance-98.90%11.85%31.25%21.15% AEON Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AEONAEON Biopharma2.9299 of 5 stars$0.77+11.6%$360.00+46,659.3%-99.0%$8.70MN/A4.285Gap DownOKUROnKure Therapeutics3.2339 of 5 stars$2.80+10.7%$32.33+1,054.8%N/A$34.18MN/A-0.58N/AESLAEstrella Immunopharma2.8877 of 5 stars$0.92+1.0%$16.00+1,640.1%-37.6%$33.73MN/A-3.54N/ACLSDClearside Biomedical2.2672 of 5 stars$0.43+0.7%$4.20+886.1%-60.1%$33.21M$1.66M-1.1530Negative NewsBTAIBioXcel Therapeutics4.5931 of 5 stars$5.67+3.5%$39.75+601.1%-52.0%$33.19M$2.27M-0.4590Short Interest ↓AKTXAkari Therapeutics2.3884 of 5 stars$1.00-1.0%$5.00+400.0%-74.2%$32.49MN/A0.009SNYRSynergy CHC4.4014 of 5 stars$3.48+1.5%$10.00+187.4%N/A$32.39M$34.83M9.1640MURAMural Oncology3.0408 of 5 stars$1.82+3.4%$12.00+559.3%-37.1%$30.49MN/A-0.21119MAAQMana Capital AcquisitionN/A$3.63-9.8%N/A+678.0%$29.49MN/A0.001CASICASI Pharmaceuticals3.7498 of 5 stars$2.26-5.0%$4.00+77.0%-62.0%$29.27M$28.54M-0.89180TRIBTrinity Biotech1.526 of 5 stars$1.57-3.1%N/A-29.9%$29.25M$61.56M-0.54480Upcoming EarningsGap Down Related Companies and Tools Related Companies OKUR Alternatives ESLA Alternatives CLSD Alternatives BTAI Alternatives AKTX Alternatives SNYR Alternatives MURA Alternatives MAAQ Alternatives CASI Alternatives TRIB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AEON) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersOne tiny company just cracked Google’s $19B problemGoogle, Microsoft, IBM… every major AI player will be forced to secure massive amounts of this material just t...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AEON Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AEON Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access